Company intelligence / Profile preview

Feng Biosciences

Waltham, Massachusetts, United Statespanaceaventure.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Feng Biosciences has two main antibody programs in clinical development, both in Phase II: navicixizumab (DLL4/VEGF bispecific monoclonal antibody) in various solid tumors and bavituximab (PS-targeting monoclonal antibody) in glioblastoma multiforme, gliosarcoma, and other solid tumors. The company utilizes the RNA expression-based Xerna TME biomarker platform for patient selection. Published results include Phase 1b and 2 trials, especially in ovarian and hepatocellular carcinoma, with ongoing use of Xerna TME to guide therapy.[2][3][5][6][7]

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBispecific monoclonal antibody
Industry: Biotech

Partnerships

Mereo BioPharma (licensing of navicixizumab)Exact Sciences (Xerna TME Panel diagnostics partnership)

Beyond the preview

Go deeper on Feng Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Feng Biosciences.

Explore the full profile